TACE联合射频消融治疗原发性肝癌患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.01.031

摘要/Abstract

摘要： 目的观察采用肝动脉化疗栓塞(TACE)联合射频消融(RFA)治疗原发性肝癌(PLC)患者的疗效。方法 2016年3月～2018年3月我院收治的PLC患者108例,采用随机数字表法将患者分为联合组和TACE组,每组54例。两组患者均接受TACE治疗,其中54例在TACE治疗的基础上联合RFA治疗。随访观察临床疗效和生存率。结果联合组有效率为77.8%,疾病控制率为87.0%,显著高于TACE组的50.0%和70.4%(P＜0.05);治疗后,联合组血清总胆红素和甲胎蛋白水平分别为(24.0±6.7)μmol/L和(135.7±15.6)μg/L,显著低于TACE治疗组【分别为(28.3±8.2)μmol/L和(226.5±18.2)μg/L,P＜0.05);在治疗期间,联合组不良反应发生率为48.2%,与TACE组的51.9%比,差异无统计学意义(P＞0.05);联合组1 a生存率为75.0%(39/52),显著高于TACE组的47.2%(25/53),差异有统计学意义(x²=8.542,P=0.003)。结论采用TACE联合RFA治疗PLC患者安全有效,可提高近期生存率,值得进一步研究。

关键词: 原发性肝癌, 肝动脉化疗栓塞, 射频消融, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of transcatheter hepatic chemoembolization (TACE) and radiofrequency ablation (RFA) in treatment of patients with primary liver cancer (PLC). Methods A total of 108 patients with PLC were recruited in our hospital between March 2016 and March 2018, and were randomly divided into two groups, with 54 in each, receiving TACE or TACE and RFA combination. All patients were followed-up for 12 months. Results After treatment, the effective rate and disease control rate in patients receiving TACE and RFA were 77.8% and 87.0%, significantly higher than 50.0% and 70.4%(P＜0.05) in TACE-treated group; one month after treatment, total serum bilirubin and alpha-fetoprotein levels in combination-treated group were (24.0±6.7)μmol/L and (135.7±15.6)μg/L, significantly lower than 【(28.3±8.2)μmol/L and (226.5±18.2)μg/L, respectively, P＜0.05) in TACE-treated group; during the treatment, the incidence in TACE- and RFA-treated patients was 48.2%, not significantly different compared to 51.9% in TACE-treated group (P＞0.05); the one-year survival rate in TACE- and RFA-treated patients was 75.0%(39/52), significantly higher than, 47.2%(25/53) in TACE-treated group (x²=8.542,P=0.003).Conclusion The application of TACE and RFA combination is safe and efficacious in the treatment of patients with PLC, which might prolong the survival of patients with PLC and warrants further investigation.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Radiofrequency ablation, Therapy

乔敏, 赵一鉴, 张建巧, 景赟杭. TACE联合射频消融治疗原发性肝癌患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 119-122.

Qiao Min, Zhao Yijian,Z hang Jianqiao,et al. Efficacy of TACE and radiofrequency ablation combination in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2021, 24(1): 119-122.

参考文献

[1] Facp MAC, Go TS, Kithier K, et al. Proceedings: primary liver cancer. areview of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases. Cancer, 1974, 33(2):574-582.
[2] Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology,2018, 67(2):600-611.
[3] Benzakoun J, Ronot M, Lagadec M, et al. Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int, 2017, 37(4):583-591.
[4] Kazutaka K, Naoki H, Akira Y, et al. Successful treatment of large-size advanced hepatocellular carcinoma by transarterial chemoembolization followed by the combination therapy of percutaneous ethanol-lipiodol injection and radiofrequency ablation. Oncol Rep, 2006, 16(5):1067-1070.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6):929-946.
[6] 閤谦, 吴骋, 童林军, 等. RECIST 1.1、PERCIST 1.0、WHO及EORTC用于评价结直肠癌肝脏转移化疗后疗效的比较. 中华核医学与分子影像杂志, 2017, 37(9):559-563.
[7] Shah B K, Kandel P, Khanal A. Second primary malignancies in hepatocellular cancer - a US population-based study. Anticancer Res, 2016, 36(7):3511-3514.
[8] Yamaguchi, Kuroda, Sugitani, et al. Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles. Int J Oncol, 2017, 50(5):1749-1759.
[9] Faigel DO, Lake DF, Landreth TL, et al. Eus-guided portal injection chemotherapy for treatment of hepatic metastases: feasibility in the acute porcine model. Gastrointest Endosc, 2016, 83(2):444-446.
[10] Lam C, Yuen W, Fan S. Hepatic cryosurgery for recurrent hepatocellular carcinoma after hepatectomy: a preliminary report. J Surg Oncol, 1998, 68(2):104-106.
[11] 赵金艳, 张一军, 刘学. 微波消融与射频消融对≤5cm单发小肝癌疗效的分析比较. 中华肿瘤防治杂志, 2018, 25(2):76-77.
[12] Aliberti C, Carandina R, Sarti D, et al. Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy. Anticancer Res, 2016, 36(7):3515-3521.
[13] Napoletano C, Taurino F, Biffoni M, et al. Rfa strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol, 2008, 32(2):481-490.
[14] 郭斌, 吴增城, 张宪光, 等. 肝动脉栓塞化疗治疗肝癌的应用进展. 中华肝胆外科杂志, 2016, 22(2):137-141.
[15] 王永华, 吴庭苗. 经导管肝动脉化疗栓塞术联合125I放射性粒子治疗肝癌的临床应用现状及进展. 中华核医学与分子影像杂志, 2019, 39(2):112-115.
[16] Zhang R, Tian X, Qin L, et al. Factors predictingabnormal liver function tests induced by graves’disease alone: a retrospective cohort study. Medicine (Baltimore), 2015, 94(19):e839.
[17] Hira K, Tariq RM, Sultana V, et al. Effect of seaweeds occurring at Karachi coast on mosquito larvae and liver function in rats. Pak J Pharm Sci, 2017, 30(2):387-391.
[18] Neel HB, Ritts RE. Transfer of tumor-specific immunity with syngeneic spleen cells and serum from mice that have large tumors and metastases. Cancer, 1977, 40(4):1643-1649.
[19] Hude I, Sasse S, Engert A, et al. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica, 2017, 102(1):30-42.
[20] Hofer U . Microbiome: the microbiota's cryptic message. Nat Rev Microbiol, 2017, 15(12):708-709.